The Asia pacific alopecia Market was worth USD 2 billion in 2022 and is estimated to be growing at a CAGR of 10.77%, to reach USD 3.34 billion by 2027.
Alopecia is a medical condition that refers to sudden, excessive hair loss on the head area, mostly in circular patches. One such type of alopecia - Alopecia areata is a common autoimmune disease that causes baldness that results in partial or complete hair loss
The primary driver of the APAC alopecia market is the rising demand for effective hair loss treatment pharmaceuticals, particularly oral treatments. Oral hair loss treatment medicines are becoming more popular since they help to ensure patient safety by reducing the number of prescription dosages while increasing therapeutic efficacy.
Other factors expected to fuel the market growth for alopecia treatment over the forecast period include increased stress levels among working-class populations, cosmeceutical drug manufacturers focusing on expanding their hair treatment and scalp treatment product lines, and cytokine therapy gaining traction for alopecia treatment. The majority of laser treatment services are not reimbursed by either public or private payers. Such services have a wide range of prices, and there is no way to standardize them.
Due to increased penetration of alopecia products, rising disposable income, and expanding consumer spending, the market in the Asia Pacific is expected to grow at the fastest rate throughout the forecast period. Furthermore, as the regulatory environment in emerging nations improves, multinational businesses are expected to invest and take advantage of the available market prospects.
However, The growth of the APAC alopecia treatment market is projected to be hampered by the patent expiration of major pharmaceuticals, resulting in market exclusivity for particular brands and significant adverse effects connected with hair loss treatments. Allergies, melancholy, and the possibility of chronic sexual dysfunction are some of the negative effects. Limited efficacy of hair loss treatment pharmaceuticals and a lack of reimbursement facilities for hair loss treatment services, such as laser treatments, are further market deterrents. The market's expansion is also being hampered by limited efficacy and a lack of evidence demonstrating the therapeutic usefulness of present hair loss medicines.
This research report on the APAC alopecia market has been segmented and sub-segmented into the following categories:
By Disease Type:
By Sales Channel:
By End Use:
Asia-Pacific is expected to develop at the quickest CAGR because alopecia treatment (hair loss) is rapidly expanding in Asia-Pacific countries due to the rapidly increasing male population and increasing awareness about hair loss treatment. The Asia-Pacific market is projected to be dominated by Japan. China is one of the world's leading countries, with fast-changing lifestyles, increased medical device manufacture, and increased use of herbal supplements.
Hair loss treatment in Asia-Pacific is expected to surpass current volume consumption, which is primarily driven by an aging population and rising stress among the young, as well as pollution concerns, which are some of the key factors driving the APAC alopecia market. Growing pollution and dietary changes are causing greater hair loss issues in developing countries such as China and India, which is predicted to affect hair loss treatment product sales in these countries. The iGrow laser system by Apira Science was approved by the China Food and Drug Administration, making it the first laser-based hair growth technology to be certified in China.
KEY MARKET PLAYERS:
Invacare Corporation, Carex Health Brands, Ottobock, Sunrise Medical Limited, Drive Medical Design & Manufacturing, Pride Mobility Products Corp., and GF Health Products, Inc. are a few of the prominent companies operating in the APAC alopecia market.
1.1 Market Definition
1.2 Scope of the report
1.3 Study Assumptions
1.4 Base Currency, Base Year and Forecast Periods
2. Research Methodology
2.1 Analysis Design
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Data Modelling
2.2.4 Expert Validation
2.3 Study Timeline
3. Report Overview
3.1 Executive Summary
3.2 Key Inferences
4. Market Dynamics
4.1 Impact Analysis
4.2 Regulatory Environment
4.3 Technology Timeline & Recent Trends
5. Competitor Benchmarking Analysis
5.1 Key Player Benchmarking
5.1.1 Market share analysis
5.1.3 Regional Presence
5.2 Mergers & Acquisition Landscape
5.3 Joint Ventures & Collaborations
6. Market Segmentation
6.1 APAC Alopecia Market – By Disease Type:
6.1.1 Alopecia Areata
6.1.2 Cicatricial Alopecia
6.1.3 Traction Alopecia
6.1.4 Alopecia Totalis
6.1.5 Alopecia Universalis
6.1.6 Androgenetic Alopecia
6.1.8 Market Size Estimations & Forecasts (2022 - 2027)
6.1.9 Y-o-Y Growth Rate Analysis
6.1.10 Market Attractiveness Index
6.2 APAC Alopecia Market – By Treatment
6.2.3 Market Size Estimations & Forecasts (2022 - 2027)
6.2.4 Y-o-Y Growth Rate Analysis
6.2.5 Market Attractiveness Index
6.3 APAC Alopecia Market – By Gender:
6.3.3 Market Size Estimations & Forecasts (2022 - 2027)
6.3.4 Y-o-Y Growth Rate Analysis
6.3.5 Market Attractiveness Index
6.4 APAC Alopecia Market – By Sales Channel:
6.4.3 Market Size Estimations & Forecasts (2022 - 2027)
6.4.4 Y-o-Y Growth Rate Analysis
6.4.5 Market Attractiveness Index
6.5 APAC Alopecia Market – By End Use:
6.5.1 Homecare Settings
6.5.2 Dermatology Clinics
6.5.3 Market Size Estimations & Forecasts (2022 - 2027)
6.5.4 Y-o-Y Growth Rate Analysis
6.5.5 Market Attractiveness Index
7. Geographical Landscape
7.1 Asia Pacific
7.1.1 By Country
22.214.171.124 South Korea
126.96.36.199 South East Asia
188.8.131.52 Australia & NZ
184.108.40.206 Rest of Asia-Pacific
7.1.2 By Disease Type:
7.1.3 By Treatment:
7.1.4 By Gender:
7.1.5 By Sales Channel:
7.1.6 By End Use:
8. Key Player Analysis
8.1 Johnson & Johnson, Inc.
8.1.1 Business Description
8.1.4 SWOT Analysis
8.1.5 Recent Developments
8.1.6 Analyst Overview
8.2 Merck & Co., Inc.
8.3 Teva Pharmaceutical Industries Ltd.
8.4 Dr. Reddy’s Laboratories Ltd.
8.5 Cipla Ltd.
8.6 Cellmid Ltd.
8.7 The Himalaya Drug Company
8.8 Taisho Pharmaceutical Holdings Co., Ltd
8.9 Shiseido Co., Ltd
8.10 Zhangguang 101 Science & Technology Co., Ltd
9. Market Outlook & Investment Opportunities
List of Tables
List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.